RPS27L
gene geneOn this page
Summary
RPS27L (ribosomal protein S27 like, HGNC:18476) is a protein-coding gene on chromosome 15q22.2, encoding Ribosomal protein eS27-like (Q71UM5).
This gene encodes a protein sharing 96% amino acid similarity with ribosomal protein S27, which suggests the encoded protein may be a component of the 40S ribosomal subunit.
Source: NCBI Gene 51065 — RefSeq curated summary.
At a glance
- GWAS associations: 2
- Clinical variants (ClinVar): 7 total
- Druggable target: yes
- MANE Select transcript:
NM_015920
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:18476 |
| Approved symbol | RPS27L |
| Name | ribosomal protein S27 like |
| Location | 15q22.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Ensembl gene | ENSG00000185088 |
| Ensembl biotype | protein_coding |
| OMIM | 612055 |
| Entrez | 51065 |
Gene structure
Transcript identifiers
Ensembl transcripts: 10 — 8 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined
ENST00000330964, ENST00000411926, ENST00000439025, ENST00000455271, ENST00000462430, ENST00000482846, ENST00000559763, ENST00000635699, ENST00000879550, ENST00000935562
RefSeq mRNA: 1 — MANE Select: NM_015920
NM_015920
CCDS: CCDS42048
Canonical transcript exons
ENST00000330964 — 4 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001312982 | 63148249 | 63154060 |
| ENSE00001536531 | 63157400 | 63157477 |
| ENSE00001697327 | 63155621 | 63155731 |
| ENSE00003688697 | 63156413 | 63156521 |
Expression profiles
Bgee: expression breadth ubiquitous, 288 present calls, max score 99.64.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 332.2366 / max 4580.5657, expressed in 1825 samples.
FANTOM5 promoters (4 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 150409 | 330.9936 | 1825 |
| 150411 | 0.6172 | 362 |
| 150408 | 0.4215 | 202 |
| 150410 | 0.2042 | 71 |
Top tissues by expression
288 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| seminal vesicle | UBERON:0000998 | 99.64 | gold quality |
| choroid plexus epithelium | UBERON:0003911 | 99.63 | gold quality |
| jejunal mucosa | UBERON:0000399 | 99.48 | gold quality |
| palpebral conjunctiva | UBERON:0001812 | 99.41 | gold quality |
| parotid gland | UBERON:0001831 | 99.41 | gold quality |
| nephron tubule | UBERON:0001231 | 99.38 | gold quality |
| mucosa of sigmoid colon | UBERON:0004993 | 99.35 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 99.24 | gold quality |
| colonic mucosa | UBERON:0000317 | 99.23 | gold quality |
| body of pancreas | UBERON:0001150 | 99.22 | gold quality |
| cauda epididymis | UBERON:0004360 | 99.20 | gold quality |
| right adrenal gland | UBERON:0001233 | 99.17 | gold quality |
| renal medulla | UBERON:0000362 | 99.16 | gold quality |
| adrenal cortex | UBERON:0001235 | 99.14 | gold quality |
| visceral pleura | UBERON:0002401 | 99.10 | gold quality |
| caput epididymis | UBERON:0004358 | 99.10 | gold quality |
| cardia of stomach | UBERON:0001162 | 99.09 | gold quality |
| pylorus | UBERON:0001166 | 99.09 | gold quality |
| left adrenal gland | UBERON:0001234 | 99.09 | gold quality |
| oocyte | CL:0000023 | 99.08 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 99.08 | gold quality |
| calcaneal tendon | UBERON:0003701 | 99.06 | gold quality |
| superficial temporal artery | UBERON:0001614 | 99.05 | gold quality |
| duodenum | UBERON:0002114 | 99.05 | gold quality |
| thoracic aorta | UBERON:0001515 | 99.03 | gold quality |
| descending thoracic aorta | UBERON:0002345 | 99.03 | gold quality |
| ascending aorta | UBERON:0001496 | 99.02 | gold quality |
| corpus epididymis | UBERON:0004359 | 98.98 | gold quality |
| pleura | UBERON:0000977 | 98.97 | gold quality |
| mammary duct | UBERON:0001765 | 98.96 | gold quality |
Single-cell (SCXA)
Detected in 14 experiment(s), a significant marker in 5.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-HCAD-1 | yes | 44.52 |
| E-HCAD-5 | yes | 39.11 |
| E-CURD-46 | yes | 19.29 |
| E-MTAB-8142 | yes | 13.27 |
| E-MTAB-8495 | no | 2039.15 |
| E-MTAB-8205 | no | 1750.56 |
| E-MTAB-9689 | no | 1510.27 |
| E-MTAB-7381 | no | 671.29 |
| E-HCAD-6 | no | 542.31 |
| E-HCAD-56 | no | 432.91 |
| E-GEOD-93593 | no | 12.97 |
| E-MTAB-6678 | no | 7.76 |
| E-MTAB-8410 | no | 3.46 |
| E-ANND-3 | no | 0.00 |
Regulation
Is transcription factor: no
Upstream regulators (CollecTRI, top): TP53
miRNA regulators (miRDB)
53 targeting RPS27L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-7110-3P | 100.00 | 73.18 | 2486 |
| HSA-MIR-5011-5P | 100.00 | 83.46 | 5820 |
| HSA-MIR-3613-3P | 100.00 | 76.36 | 7965 |
| HSA-MIR-190A-3P | 100.00 | 80.35 | 5520 |
| HSA-MIR-371B-5P | 99.99 | 75.34 | 4759 |
| HSA-MIR-373-5P | 99.98 | 75.36 | 4753 |
| HSA-MIR-616-5P | 99.98 | 75.58 | 4775 |
| HSA-MIR-1468-3P | 99.96 | 72.74 | 3797 |
| HSA-MIR-548AA | 99.96 | 70.64 | 3753 |
| HSA-MIR-548AP-3P | 99.96 | 70.64 | 3753 |
| HSA-MIR-548T-3P | 99.96 | 70.64 | 3753 |
| HSA-MIR-3686 | 99.90 | 70.53 | 2432 |
| HSA-MIR-6780A-5P | 99.88 | 66.69 | 2776 |
| HSA-MIR-6124 | 99.87 | 69.78 | 3551 |
| HSA-MIR-548AR-3P | 99.85 | 71.26 | 3889 |
| HSA-MIR-4728-5P | 99.85 | 69.39 | 4718 |
| HSA-MIR-1323 | 99.83 | 69.89 | 2471 |
| HSA-MIR-548AZ-3P | 99.82 | 70.56 | 3549 |
| HSA-MIR-548BC | 99.82 | 70.61 | 3524 |
| HSA-MIR-548E-3P | 99.82 | 70.59 | 3514 |
| HSA-MIR-548F-3P | 99.82 | 70.59 | 3540 |
| HSA-MIR-323A-3P | 99.79 | 70.30 | 1739 |
| HSA-MIR-1273H-5P | 99.77 | 66.32 | 2471 |
| HSA-MIR-548A-3P | 99.76 | 70.58 | 3524 |
| HSA-MIR-548O-3P | 99.74 | 69.30 | 2228 |
| HSA-MIR-4719 | 99.73 | 72.10 | 3329 |
| HSA-MIR-4524A-3P | 99.72 | 66.85 | 2406 |
| HSA-MIR-12129 | 99.72 | 67.45 | 1311 |
| HSA-MIR-30B-3P | 99.70 | 65.76 | 2325 |
| HSA-MIR-3689A-3P | 99.70 | 65.73 | 2306 |
Literature-anchored findings (GeneRIF, showing 4)
- Elevated RPS27L may improve the prognoses of certain colorectal cancer patients by enhancing the DNA repair capacity of their colonic cells. (PMID:23826192)
- The study suggests that RPS27L reduction might play a promoting role during breast tumorigenesis by autophagy induction via the beta-TrCP-DEPTOR-mTORC1 axis. (PMID:30425236)
- Neddylation modification of ribosomal protein RPS27L or RPS27 by MDM2 or NEDP1 regulates cancer cell survival. (PMID:32779270)
- Inactivation of ribosomal protein S27-like impairs DNA interstrand cross-link repair by destabilization of FANCD2 and FANCI. (PMID:33051438)
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | rps27l | ENSDARG00000100513 |
| mus_musculus | Rps27l | ENSMUSG00000036781 |
| rattus_norvegicus | Rps27l | ENSRNOG00000050473 |
Paralogs (1): RPS27 (ENSG00000177954)
Protein
Protein identifiers
Ribosomal protein eS27-like — Q71UM5 (reviewed: Q71UM5)
Alternative names: 40S ribosomal protein S27-like, Small ribosomal subunit protein eS27-like
All UniProt accessions (4): Q71UM5, C9J1C5, C9JLI6, H0YMV8
UniProt curated annotations — full annotation on UniProt →
Cofactor. Binds 1 zinc ion per subunit.
Similarity. Belongs to the eukaryotic ribosomal protein eS27 family.
RefSeq proteins (1): NP_057004* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000592 | Ribosomal_eS27 | Family |
| IPR011332 | Ribosomal_zn-bd | Homologous_superfamily |
| IPR023407 | Ribosomal_eS27_Zn-bd_dom_sf | Homologous_superfamily |
Pfam: PF01667
UniProt features (5 total): chain 1, zinc finger region 1, region of interest 1, compositionally biased region 1, sequence conflict 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q71UM5-F1 | 92.93 | 0.89 |
Function
Pathways and Gene Ontology
Reactome pathways
50 pathways
| ID | Pathway |
|---|---|
| R-HSA-156827 | L13a-mediated translational silencing of Ceruloplasmin expression |
| R-HSA-156902 | Peptide chain elongation |
| R-HSA-1799339 | SRP-dependent cotranslational protein targeting to membrane |
| R-HSA-192823 | Viral mRNA Translation |
| R-HSA-2408557 | Selenocysteine synthesis |
| R-HSA-6791226 | Major pathway of rRNA processing in the nucleolus and cytosol |
| R-HSA-72649 | Translation initiation complex formation |
| R-HSA-72689 | Formation of a pool of free 40S subunits |
| R-HSA-72695 | Formation of the ternary complex, and subsequently, the 43S complex |
| R-HSA-72702 | Ribosomal scanning and start codon recognition |
| R-HSA-72706 | GTP hydrolysis and joining of the 60S ribosomal subunit |
| R-HSA-72764 | Eukaryotic Translation Termination |
| R-HSA-9010553 | Regulation of expression of SLITs and ROBOs |
| R-HSA-9633012 | Response of EIF2AK4 (GCN2) to amino acid deficiency |
| R-HSA-9735869 | SARS-CoV-1 modulates host translation machinery |
| R-HSA-9754678 | SARS-CoV-2 modulates host translation machinery |
| R-HSA-975956 | Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) |
| R-HSA-975957 | Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) |
| R-HSA-9954714 | PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA |
| R-HSA-9954716 | ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA |
| R-HSA-1266738 | Developmental Biology |
| R-HSA-1430728 | Metabolism |
| R-HSA-156842 | Eukaryotic Translation Elongation |
| R-HSA-1643685 | Disease |
| R-HSA-168255 | Influenza Infection |
| R-HSA-168273 | Influenza Viral RNA Transcription and Replication |
| R-HSA-2262752 | Cellular responses to stress |
| R-HSA-2408522 | Selenoamino acid metabolism |
| R-HSA-376176 | Signaling by ROBO receptors |
| R-HSA-392499 | Metabolism of proteins |
MSigDB gene sets: 273 (showing top):
GOBP_RIBOSOME_BIOGENESIS, GOBP_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY_IN_RESPONSE_TO_DNA_DAMAGE_BY_P53_CLASS_MEDIATOR, MODULE_151, SHEPARD_CRASH_AND_BURN_MUTANT_UP, GOBP_CELL_CYCLE_PHASE_TRANSITION, JOHANSSON_GLIOMAGENESIS_BY_PDGFB_UP, GOBP_RIBOSOME_ASSEMBLY, CHANDRAN_METASTASIS_DN, GOBP_TRANSLATION, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION, CAIRO_HEPATOBLASTOMA_CLASSES_DN, GOMF_TRANSLATION_REGULATOR_ACTIVITY, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS, GOBP_APOPTOTIC_SIGNALING_PATHWAY, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE
GO Biological Process (6): ribosomal small subunit assembly (GO:0000028), translation (GO:0006412), DNA damage response, signal transduction by p53 class mediator (GO:0030330), mitotic G1 DNA damage checkpoint signaling (GO:0031571), intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator (GO:0042771), positive regulation of translation (GO:0045727)
GO Molecular Function (6): RNA binding (GO:0003723), structural constituent of ribosome (GO:0003735), zinc ion binding (GO:0008270), translation activator activity (GO:0008494), protein binding (GO:0005515), metal ion binding (GO:0046872)
GO Cellular Component (4): nucleus (GO:0005634), cytosolic small ribosomal subunit (GO:0022627), ribosome (GO:0005840), ribonucleoprotein complex (GO:1990904)
Reactome top-level categories
Rollup of top-14 pathways:
| Category | Pathways |
|---|---|
| Cap-dependent Translation Initiation | 4 |
| Translation | 2 |
| Nonsense-Mediated Decay (NMD) | 2 |
| Ribosome-associated quality control | 2 |
| Eukaryotic Translation Initiation | 1 |
| Eukaryotic Translation Elongation | 1 |
| Influenza Viral RNA Transcription and Replication | 1 |
| Selenoamino acid metabolism | 1 |
| rRNA processing in the nucleus and cytosol | 1 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 1 |
| Signaling by ROBO receptors | 1 |
| Cellular response to starvation | 1 |
| SARS-CoV-1-host interactions | 1 |
| SARS-CoV-2-host interactions | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| protein-RNA complex assembly | 1 |
| ribosome assembly | 1 |
| ribosomal small subunit biogenesis | 1 |
| peptidyltransferase activity | 1 |
| translational initiation | 1 |
| translational elongation | 1 |
| translational termination | 1 |
| macromolecule biosynthetic process | 1 |
| protein metabolic process | 1 |
| protein biosynthetic process | 1 |
| signal transduction in response to DNA damage | 1 |
| signal transduction by p53 class mediator | 1 |
| mitotic G1 phase | 1 |
| mitotic DNA damage checkpoint signaling | 1 |
| mitotic G1/S transition checkpoint signaling | 1 |
| intrinsic apoptotic signaling pathway in response to DNA damage | 1 |
| intrinsic apoptotic signaling pathway by p53 class mediator | 1 |
| translation | 1 |
| regulation of translation | 1 |
| positive regulation of gene expression | 1 |
| positive regulation of protein metabolic process | 1 |
| nucleic acid binding | 1 |
| structural molecule activity | 1 |
| ribosome | 1 |
| transition metal ion binding | 1 |
| translation regulator activity | 1 |
| positive regulation of translation | 1 |
| binding | 1 |
| cation binding | 1 |
| intracellular membrane-bounded organelle | 1 |
| small ribosomal subunit | 1 |
| cytosolic ribosome | 1 |
| intracellular membraneless organelle | 1 |
| protein-containing complex | 1 |
Protein interactions and networks
STRING
2651 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| RPS27L | RPL11 | P25121 | 710 |
| RPS27L | RPL15 | P39030 | 676 |
| RPS27L | RPL21 | P46778 | 674 |
| RPS27L | RPL38 | P23411 | 671 |
| RPS27L | RPL22 | P35268 | 655 |
| RPS27L | RPS14 | P06366 | 637 |
| RPS27L | RPL7 | P18124 | 637 |
| RPS27L | RPL8 | P25120 | 622 |
| RPS27L | RPL22L1 | Q6P5R6 | 617 |
| RPS27L | RPL26 | P61254 | 615 |
| RPS27L | RPL5 | P46777 | 609 |
| RPS27L | RPL9 | P32969 | 605 |
| RPS27L | RPS19 | P39019 | 580 |
| RPS27L | TP53 | P04637 | 575 |
| RPS27L | RPS25 | P25111 | 569 |
IntAct
115 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| RPS27L | MDM2 | psi-mi:“MI:0407”(direct interaction) | 0.620 |
| MDM2 | RPS27L | psi-mi:“MI:0915”(physical association) | 0.620 |
| RPS27L | MDM2 | psi-mi:“MI:0915”(physical association) | 0.620 |
| RPS27L | MDM2 | psi-mi:“MI:0403”(colocalization) | 0.620 |
| PPP2R2B | DDX3X | psi-mi:“MI:0914”(association) | 0.460 |
| ESR2 | FBLL1 | psi-mi:“MI:0914”(association) | 0.460 |
| TUBA1A | TUBAL3 | psi-mi:“MI:0914”(association) | 0.420 |
| RPS27L | RPS7 | psi-mi:“MI:0915”(physical association) | 0.400 |
| RPS27L | E7 | psi-mi:“MI:0915”(physical association) | 0.370 |
| ZMYND8 | MTA3 | psi-mi:“MI:0914”(association) | 0.350 |
| Rrbp1 | PIPSL | psi-mi:“MI:0914”(association) | 0.350 |
| Ktn1 | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
| NPM1 | RPSA | psi-mi:“MI:0914”(association) | 0.350 |
| JUN | TPM3 | psi-mi:“MI:0914”(association) | 0.350 |
| VWA8 | psi-mi:“MI:0914”(association) | 0.350 | |
| ESYT2 | psi-mi:“MI:0914”(association) | 0.350 | |
| E6 | PLOD2 | psi-mi:“MI:0914”(association) | 0.350 |
| E7 | COPE | psi-mi:“MI:0914”(association) | 0.350 |
| E5 | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
| PGRMC1 | psi-mi:“MI:0914”(association) | 0.350 | |
| HAX1 | psi-mi:“MI:0914”(association) | 0.350 | |
| BVLF1 | VWA8 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (319): RPS27L (Affinity Capture-RNA), RPS27L (Co-fractionation), RPS27L (Affinity Capture-MS), RPS27L (Affinity Capture-MS), RPS27L (Affinity Capture-MS), RPS27L (Affinity Capture-MS), RPS27L (Affinity Capture-MS), RPS27L (Affinity Capture-MS), RPS27L (Affinity Capture-MS), RPS27L (Affinity Capture-MS), RPS27L (Affinity Capture-MS), RPS27L (Affinity Capture-MS), RPS27L (Affinity Capture-MS), RPS27L (Affinity Capture-MS), RPS27L (Affinity Capture-MS)
ESM2 similar proteins: A0A1D8PTI7, A0A1L8H579, A0A1W2PPG7, A1X8D9, G1TZ76, O64650, O74330, P03131, P06459, P09003, P0C567, P0DOC8, P11332, P17387, P24051, P35997, P36826, P36833, P38711, P40569, P42677, P47903, P47904, P55833, P68834, P68835, P68958, P68959, Q02271, Q13670, Q1X709, Q2KHT7, Q39072, Q3T0B7, Q5RBK1, Q5RGZ1, Q67616, Q67708, Q6DRC3, Q6ZWU9
Diamond homologs: A0A1D8PTI7, A1RRN0, A2BN94, A3MUV2, A4WLR8, B1YAF9, B6YT34, C5A6X9, G1TZ76, O64650, O74330, P24051, P35997, P38654, P38711, P42677, P47903, P47904, P55833, P58078, Q2KHT7, Q3T0B7, Q46C77, Q4J9B1, Q5JE50, Q5RBK1, Q6ZWU9, Q6ZWY3, Q71TY3, Q71UM5, Q7RVN2, Q8L953, Q8T1V4, Q8U474, Q8ZTY4, Q96564, Q973F9, Q97Z80, Q9M2F1, Q9TXP0
SIGNOR signaling
1 interactions.
| A | Effect | B | Mechanism |
|---|---|---|---|
| RPS27L | “form complex” | “40S cytosolic small ribosomal subunit” | binding |
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 135 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Ribosomal scanning and start codon recognition | 10 | 18.7× | 1e-08 |
| Formation of the ternary complex, and subsequently, the 43S complex | 8 | 16.9× | 7e-07 |
| Translation initiation complex formation | 9 | 16.8× | 1e-07 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 6 | 16.0× | 5e-05 |
| Eukaryotic Translation Initiation | 5 | 15.1× | 4e-04 |
| Cap-dependent Translation Initiation | 5 | 15.1× | 4e-04 |
| SARS-CoV-1 modulates host translation machinery | 5 | 15.1× | 4e-04 |
| SRP-dependent cotranslational protein targeting to membrane | 15 | 14.7× | 2e-11 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| stress granule assembly | 5 | 25.9× | 2e-04 |
| translational initiation | 7 | 21.6× | 8e-06 |
| cytoplasmic translation | 13 | 20.8× | 4e-11 |
| negative regulation of translation | 8 | 13.5× | 3e-05 |
| translation | 13 | 11.5× | 4e-08 |
| ribosomal small subunit biogenesis | 5 | 9.8× | 1e-02 |
| positive regulation of translation | 5 | 9.8× | 1e-02 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
7 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 0 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1365 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 15:63126855:A:AG | acceptor_gain | 1.0000 |
| 15:63126855:AAAG:A | acceptor_gain | 1.0000 |
| 15:63126856:A:G | acceptor_gain | 1.0000 |
| 15:63126857:A:AG | acceptor_gain | 1.0000 |
| 15:63126858:G:A | acceptor_gain | 1.0000 |
| 15:63126858:G:GA | acceptor_gain | 1.0000 |
| 15:63126858:GG:G | acceptor_loss | 1.0000 |
| 15:63126858:GGTTT:G | acceptor_gain | 1.0000 |
| 15:63127044:GAAAA:G | donor_loss | 1.0000 |
| 15:63127046:AAAG:A | donor_loss | 1.0000 |
| 15:63127047:AAGG:A | donor_loss | 1.0000 |
| 15:63127049:GG:G | donor_loss | 1.0000 |
| 15:63127050:G:GA | donor_loss | 1.0000 |
| 15:63127349:TTAG:T | acceptor_loss | 1.0000 |
| 15:63127350:TAG:T | acceptor_loss | 1.0000 |
| 15:63127352:G:A | acceptor_loss | 1.0000 |
| 15:63127686:CCTGG:C | donor_loss | 1.0000 |
| 15:63127687:CTGG:C | donor_loss | 1.0000 |
| 15:63127688:TGGTG:T | donor_loss | 1.0000 |
| 15:63127689:GGTG:G | donor_loss | 1.0000 |
| 15:63127690:GTGA:G | donor_loss | 1.0000 |
| 15:63127691:T:A | donor_loss | 1.0000 |
| 15:63129468:C:A | acceptor_gain | 1.0000 |
| 15:63129471:A:AG | acceptor_gain | 1.0000 |
| 15:63129471:AAT:A | acceptor_gain | 1.0000 |
| 15:63129472:A:G | acceptor_gain | 1.0000 |
| 15:63129473:T:TA | acceptor_gain | 1.0000 |
| 15:63129646:GCAAG:G | donor_gain | 1.0000 |
| 15:63129647:CAAG:C | donor_loss | 1.0000 |
| 15:63129648:AAG:A | donor_loss | 1.0000 |
AlphaMissense
541 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 15:63155706:G:C | F47L | 1.000 |
| 15:63155706:G:T | F47L | 1.000 |
| 15:63155708:A:G | F47L | 1.000 |
| 15:63154050:A:C | F79L | 0.999 |
| 15:63154050:A:T | F79L | 0.999 |
| 15:63154052:A:G | F79L | 0.999 |
| 15:63155635:G:T | A71D | 0.999 |
| 15:63155641:C:A | G69V | 0.999 |
| 15:63155644:C:A | G68V | 0.999 |
| 15:63155644:C:T | G68E | 0.999 |
| 15:63155655:G:C | C64W | 0.999 |
| 15:63155681:A:G | C56R | 0.999 |
| 15:63155698:G:T | A50D | 0.999 |
| 15:63155703:G:C | S48R | 0.999 |
| 15:63155703:G:T | S48R | 0.999 |
| 15:63155704:C:A | S48I | 0.999 |
| 15:63155705:T:G | S48R | 0.999 |
| 15:63155708:A:T | F47I | 0.999 |
| 15:63155710:A:T | V46D | 0.999 |
| 15:63156419:A:G | C37R | 0.999 |
| 15:63156432:A:C | F32L | 0.999 |
| 15:63156432:A:T | F32L | 0.999 |
| 15:63156434:A:G | F32L | 0.999 |
| 15:63154047:T:A | R80S | 0.998 |
| 15:63154047:T:G | R80S | 0.998 |
| 15:63154048:C:A | R80I | 0.998 |
| 15:63154048:C:G | R80T | 0.998 |
| 15:63155621:C:A | G76W | 0.998 |
| 15:63155641:C:T | G69E | 0.998 |
| 15:63155656:C:T | C64Y | 0.998 |
dbSNP variants (sampled 300 via entrez): RS1000263127 (15:63153702 G>C), RS1000303088 (15:63159325 G>A), RS1000576820 (15:63157659 T>G), RS1000629049 (15:63157842 G>A), RS1000635827 (15:63158129 G>T), RS1001621754 (15:63152962 T>C), RS1001966998 (15:63152375 G>A,T), RS1002114555 (15:63157545 C>A,T), RS1002224814 (15:63151519 C>T), RS1002269833 (15:63150868 C>G), RS1002308538 (15:63157188 T>C), RS1002682070 (15:63151975 T>C), RS1002722380 (15:63156165 T>C), RS1003065590 (15:63155976 T>C), RS1003275222 (15:63150832 G>T)
Disease associations
OMIM: gene MIM:612055 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
2 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST006249_61 | Serum metabolite levels | 1.000000e-21 |
| GCST010002_172 | Refractive error | 6.000000e-36 |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: yes
ChEMBL targets (1): CHEMBL6067311 (SINGLE PROTEIN)
PharmGKB: 1 entry (VIP=true, CPIC=false)
ChEMBL bioactivities
4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).
| pChembl | Type | Value | Unit | Molecule |
|---|---|---|---|---|
| 8.37 | Kd | 4.316 | nM | CHEMBL5653589 |
| 8.37 | ED50 | 4.316 | nM | CHEMBL5653589 |
| 5.19 | Kd | 6464 | nM | CHEMBL3752910 |
| 5.19 | ED50 | 6464 | nM | CHEMBL3752910 |
PubChem BioAssay actives
2 with measured affinity, of 4 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.
| Compound | Assay | Type | Value | Unit |
|---|---|---|---|---|
| 4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide | 2149302: Binding affinity to human RPS27L incubated for 45 mins by Kinobead based pull down assay | kd | 0.0043 | uM |
| 4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide | 2149302: Binding affinity to human RPS27L incubated for 45 mins by Kinobead based pull down assay | kd | 6.4644 | uM |
CTD chemical–gene interactions
91 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Valproic Acid | affects cotreatment, increases expression, affects expression | 6 |
| bisphenol A | affects expression, decreases expression, increases expression | 4 |
| Air Pollutants | increases abundance, increases expression, decreases expression, affects cotreatment | 4 |
| Cisplatin | affects expression, increases expression | 4 |
| sodium arsenite | decreases expression, increases expression | 3 |
| Benzo(a)pyrene | increases expression | 3 |
| Fluorouracil | affects reaction, decreases expression, increases expression | 3 |
| Cadmium Chloride | decreases reaction, increases abundance, increases palmitoylation, affects expression, increases expression | 3 |
| mercuric bromide | affects cotreatment, increases expression | 2 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | affects cotreatment, increases expression | 2 |
| Cadmium | decreases reaction, increases abundance, increases palmitoylation, increases expression | 2 |
| Doxorubicin | increases expression, affects expression | 2 |
| Phenylmercuric Acetate | affects cotreatment, increases expression | 2 |
| Tunicamycin | affects expression, increases expression | 2 |
| Cyclosporine | decreases expression, increases expression | 2 |
| Particulate Matter | decreases expression, increases abundance | 2 |
| aristolochic acid I | decreases expression | 1 |
| bisphenol F | increases expression | 1 |
| dicrotophos | decreases expression | 1 |
| chloroacetaldehyde | affects expression | 1 |
| alpha-pinene | increases expression, increases abundance, affects cotreatment | 1 |
| beta-lapachone | increases expression | 1 |
| arsenite | affects binding, increases reaction | 1 |
| tris(1,3-dichloro-2-propyl)phosphate | decreases expression | 1 |
| potassium bromate | increases expression | 1 |
| 2-bromopalmitate | decreases reaction, increases abundance, increases palmitoylation | 1 |
| N-benzyloxycarbonylprolylprolinal | increases expression | 1 |
| methacrylaldehyde | affects cotreatment, increases expression, increases abundance | 1 |
| beta-methylcholine | affects expression | 1 |
| azoxystrobin | increases expression | 1 |
ChEMBL screening assays
1 unique, capped per target: 1 binding
Representative assays (with source publication via chembl_document):
| Assay ID | Type | Description | Source paper |
|---|---|---|---|
| CHEMBL5652344 | Binding | Binding affinity to human RPS27L incubated for 45 mins by Kinobead based pull down assay | NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem |
Cellosaurus cell lines
1 cell lines: 1 cancer cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_B2E5 | Abcam HeLa RPS27L KO | Cancer cell line | Female |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.